Template:Dgfn2015 Mo 7:00 PCSK9
From HOP house of papers
Revision as of 13:15, 14 September 2015 by Ossip Groth (Talk | contribs)
| Journal article, free access |
| GET A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Extract PDF direct |
| Journal article, free access |
| GET Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates Extract PDF direct |
| Journal article, free access |
| GET The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Extract PDF direct |
| Journal article, free access |
| GET Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Extract PDF direct |
| Journal article, free access |
| GET A century of cholesterol and coronaries: from plaques to genes to statins Extract PDF direct |
| Journal article, free access |
| GET Targeting PCSK9 for hypercholesterolemia Extract PDF direct |
| Journal article, free access |
| GET The biology and therapeutic targeting of the proprotein convertases Extract PDF direct |
| Journal article, free access |
| GET Plasma membrane CD81 complexes with PCSK9 and LDLR and its levels are reduced by PCSK9 Extract PDF direct |
| Journal article, free access |
| GET Protease variants, LDL, and coronary heart disease Extract PDF direct |
